A Lancet paper is sparking excitement about an investigational cell therapy for spina bifida. Here’s the study: Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study. Myelomeningocele is the most severe manifestation of spina bifida The work was led by my UC Davis colleagues Diana Farmer and Aijun Wang. The trial is […]
The post Early encouraging UC Davis trial data on cell therapy for spina bifida appeared first on The Niche.